Cholesterol
Cholesterol is a sterol lipid that is an important structural and regulatory component of cellular membranes.
Cholesterol is a sterol lipid that is an important structural and regulatory component of cellular membranes. Its distribution between the plasma membrane, endoplasmic reticulum (ER), and other intracellular compartments is tightly controlled. Cholesterol contributes to the organization and physical properties of the lipid bilayer and participates in membrane-dependent processes, including signaling, vesicular transport, and cellular motility. Cellular cholesterol balance reflects coordinated biosynthesis, uptake, intracellular trafficking, esterification, and degradation.
In medicine, cholesterol is measured in blood as a clinical metric relevant to metabolic health and cardiovascular risk assessment. Disturbances in cholesterol homeostasis include hypercholesterolemia and may occur alongside obesity, triglyceride abnormalities, type 2 diabetes, inflammation, or metabolic dysfunction–associated steatotic liver disease. The recent literature represented here also treats cholesterol as a therapeutic target, a component of lipid nanoparticle formulations, a substrate for cholesterol oxidase, and a regulator of cancer-cell behavior. In particular, Aster proteins transport cholesterol from the plasma membrane to the ER, linking membrane cholesterol to intracellular sensing and metabolism 42679036Sep.
- Admission low-density lipoprotein cholesterol and early haematoma expansion after spontaneous intracerebral haemorrhage. PMID 42751819
Where the papers sit
12 papers study cholesterol directly. The themes below are drawn from those 12. 1 paradigm shift and 1 new direction follow.
-
Cholesterol-Related Disease Biology : Cholesterol-related work here spans cancer progression, membrane signaling, hepatic metabolism, obesity, trafficking inhibitors and diagnostic sensing. The cluster lacks a single direction, linking diverse applications through cholesterol biology rather than a shared therapeutic strategy. 8 papers · 66.7%
-
Liver-Targeted mRNA Delivery : Lipid nanoparticle design is moving toward component-level optimization and hepatocyte targeting. Cholesterol-free formulations, DY635-functionalized lipids, particle size and traceability recur as priorities for safer, more precise mRNA delivery. 2 papers · 16.7%
-
LDL Cholesterol Risk Management : Admission LDL cholesterol is being evaluated as a marker of early hematoma expansion, while personalized health coaching lowers LDL and improves lipid control. The cluster combines prognostic risk assessment with active cardiovascular risk management. 2 papers · 16.7%
Cholesterol is not obligatory for effective lipid-nanoparticle delivery and can instead constrain tissue targeting
The mRNA lipid-nanoparticle component study and the DY635-functionalized cholesterol-free lipid-nanoparticle study found that removing cholesterol did not universally abolish delivery: cholesterol was dispensable for extrahepatic delivery, while cholesterol-free formulations altered expression distribution and enabled incorporation of targeting ligands rather than producing the conventional predominantly hepatic pattern 42503852Jul 42309200Jun. This overturns the assumption that cholesterol is an indispensable structural helper and that its presence is compatible with broad tissue targeting, shifting formulation design toward selectively retaining or eliminating cholesterol according to the desired organ destination.
A cholesterol modification converts a CXCR4-inhibitor polymer into a mitochondria-targeting inhibitor of ATP synthase
The PAMD-Ch17 polymeric analog of plerixafor in T-cell acute lymphoblastic leukemia found that its cholesterol-modified polymer, unlike AMD3100, localized to mitochondria, bound ATP synthase, impaired mitochondrial respiration, and killed cells independently of CXCR4 41893624Mar. This assigns cholesterol a role as a drug-engineering determinant of mitochondrial localization and bioenergetic inhibition, rather than as a metabolic substrate, membrane regulator, delivery component, or therapeutic depletion target.
Recent Findings on Cholesterol
Cholesterol-Related Disease Biology: DHCR24 and intracellular cholesterol availability link cholesterol biology to cancer progression, migration, and cellular senescence. DHCR24 promoted endometrial carcinoma growth and suppressed p53/p21/p16-related senescence, while statin-mediated cholesterol reduction impaired melanoma amoeboid migration through Piezo1 and intracellular Ca2+ signaling 42742784Sep42715085Sep. Cholesterol manipulation also produced context-dependent metabolic effects: hepatic ACAT3 overexpression improved glucose and lipid metabolism, whereas ACAT3 loss altered bile acid profiles, gut microbiota, and energy expenditure 42264322Jun. Selective Aster inhibitors now enable isoform-resolved control of cholesterol trafficking, while cholesterol oxidase-containing nanozymes and chemiluminescence-functionalized magnetic nanoparticles extend cholesterol biology toward prostate cancer immunotherapy and serum sensing 42679036Sep42424164Jul42393242Jul. Population data further show that non-HDL cholesterol differences between obesity and normal BMI have narrowed in older adults, whereas PAMD-Ch17 uses a cholesterol modification to drive CXCR4-independent mitochondrial dysfunction in T-ALL cells 42385750Jul41893624Mar.
Liver-Targeted mRNA Delivery: Ionizable lipids govern mRNA delivery efficacy, while cholesterol and other helper lipids shape organ tropism, particle size, and inflammation. Cholesterol supports efficient liver-targeted delivery but remains dispensable for extrahepatic delivery, and phospholipid-free formulations reduce inflammation 42503852Jul. Cholesterol-free blue lipid nanoparticles altered expression distribution and enabled incorporation of the hepatocyte-targeting DSPE-DY635 lipid. DSPE-DY635 also provided traceable uptake and increased mRNA expression in HuH7 hepatocytes, directing formulation work toward modular targeting and particle tracking 42309200Jun.
LDL Cholesterol Risk Management: Lower admission LDL-C was associated with early haematoma expansion after spontaneous intracerebral haemorrhage, but adding LDL-C provided limited predictive value beyond clinical and imaging factors 42751819Sep. A health coach-based strategy instead produced an actionable LDL-C reduction in veterans with atherosclerotic cardiovascular disease through medication-adherence assessment, motivational interviewing, lifestyle support, and medication intensification 42714414Sep. These findings place LDL-C in two complementary roles: a prognostic marker requiring external validation and a modifiable treatment target. Future management therefore depends on validating LDL-C risk thresholds while personalizing adherence and lipid-lowering interventions.
Written from 12 PubMed abstracts, each one cited by PMID above. Published: 2026-09-11. Last written: 2026-09-19 by GPT. Drafted by language models from published abstracts; not medical advice.